X4 Pharmaceuticals
XFOR
97 hedge funds and large institutions have $67.3M invested in X4 Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 36 increasing their positions, 18 reducing their positions, and 11 closing their positions.
163% more call options, than puts
Call options by funds: $279K | Put options by funds: $106K
100% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 18
14% more capital invested
Capital invested by funds: $58.9M → $67.3M (+$8.41M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
0.03% less ownership
Funds ownership: 2.02% → 1.99% (-0.03%)
1% less funds holding
Funds holding: 98 → 97 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$992K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$453K |
| 3 |
BlackRock
New York
|
+$372K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$353K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$270K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.35M |
| 2 |
SCM
Sio Capital Management
New York
|
-$832K |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$382K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$278K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$132K |
XFOR Hedge Fund Activity: Q3 2024 in Review
97 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2024, worth a combined $67.3M — up 14% from $58.9M a quarter earlier.
Fund positioning in XFOR was balanced in Q3 2024: 11 funds opened new positions, 11 closed out, 36 added to existing stakes and 18 trimmed.
The largest buyer was Pale Fire Capital SE, adding an estimated $992K. The largest seller was Soleus Capital Management, exiting entirely with an estimated $2.35M sold.
- 97 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2024, down from 98 in Q2 2024.
- Funds reported $67.3M of X4 Pharmaceuticals stock for Q3 2024, up 14% quarter-over-quarter.
- 11 funds opened new X4 Pharmaceuticals positions in Q3 2024 and 11 closed out, a net change of 0 holders.
- The largest X4 Pharmaceuticals buyer in Q3 2024 was Pale Fire Capital SE, an estimated $992K added.
- The largest X4 Pharmaceuticals seller in Q3 2024 was Soleus Capital Management, an estimated $2.35M sold.
Based on aggregated 13F filings for Q3 2024.